Vir Biotechnology Inc. [NASDAQ: VIR] closed the trading session at $25.51 on 11/09/20. The day’s price range saw the stock hit a low of $25.50, while the highest price level was $29.96. The company report on November 6, 2020 that Vir Biotechnology Publishes New Research Characterizing Variation in the SARS-CoV-2 Spike Protein and Virulence of a Prevalent Immune Evasion Variant, N439K.
– Manuscript highlights the importance of molecular surveillance of SARS-CoV-2 immune evasion and rational design of vaccines and antibody therapies for COVID-19 –.
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the publication of new research demonstrating that the immunodominant SARS-CoV-2 receptor binding motif (RBM) is the least conserved region in the SARS-CoV-2 spike protein, allowing for the occurrence of mutations without disrupting human ACE2 (hACE2) binding, which mediates viral entry. Researchers also characterize the virulence and fitness of N439K, a prevalent variant in the RBM that demonstrated resistance to human neutralizing monoclonal antibodies (mAbs), including one that is currently being evaluated in clinical trials. The manuscript, which was developed by Vir in collaboration with the MRC-University of Glasgow Centre for Virus Research, was published online November 5, 2020 on bioRxiv, and has been submitted to a peer-reviewed journal for future print publication.
The stocks have a year to date performance of 102.86 percent and weekly performance of -17.01 percent. The stock has been moved at -15.70 percent over the last six months. The stock has performed -37.61 percent around the most recent 30 days and changed -51.56 percent over the most recent 3-months.
If compared to the average trading volume of 1.14M shares, VIR reached to a volume of 3515920 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Vir Biotechnology Inc. [VIR]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for VIR shares is $55.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on VIR stock is a recommendation set at 2.40. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
BofA Securities have made an estimate for Vir Biotechnology Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on October 05, 2020. While these analysts kept the previous recommendation, Goldman raised their target price from $48 to $54. The new note on the price target was released on September 14, 2020, representing the official price target for Vir Biotechnology Inc. stock. Previously, the target price had yet another raise to $29, while JP Morgan analysts kept a Neutral rating on VIR stock.
The Average True Range (ATR) for Vir Biotechnology Inc. is set at 2.86, with the Price to Sales ratio for VIR stock in the period of the last 12 months amounting to 41.67. The Price to Book ratio for the last quarter was 5.21, with the Price to Cash per share for the same quarter was set at 4.50.
VIR stock trade performance evaluation
Vir Biotechnology Inc. [VIR] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -17.01. With this latest performance, VIR shares dropped by -37.61% in over the last four-week period, additionally sinking by -15.70% over the last 6 months – not to mention a rise of 84.45% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for VIR stock in for the last two-week period is set at 32.52, with the RSI for the last a single of trading hit 24.50, and the three-weeks RSI is set at 34.58 for Vir Biotechnology Inc. [VIR]. The present Moving Average for the last 50 days of trading for this stock 34.62, while it was recorded at 30.53 for the last single week of trading, and 36.46 for the last 200 days.
Vir Biotechnology Inc. [VIR]: An insightful look at the core fundamentals
Vir Biotechnology Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 10.50 and a Current Ratio set at 10.50.
Earnings per share (EPS) analysis for Vir Biotechnology Inc. [VIR] stock
With the latest financial reports released by the company, Vir Biotechnology Inc. posted -4.6/share EPS, while the average EPS was predicted by analysts to be reported at -3.71/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -24.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for VIR. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Vir Biotechnology Inc. go to 9.00%.
Vir Biotechnology Inc. [VIR]: Insider Ownership positions
There are presently around $1,360 million, or 75.80% of VIR stock, in the hands of institutional investors. The top three institutional holders of VIR stocks are: SB INVESTMENT ADVISERS (UK) LTD with ownership of 22,616,666, which is approximately 0% of the company’s market cap and around 0.40% of the total institutional ownership; TEMASEK HOLDINGS (PRIVATE) LTD, holding 5,499,999 shares of the stock with an approximate value of $140.31 million in VIR stocks shares; and ALASKA PERMANENT FUND CORP, currently with $122.45 million in VIR stock with ownership of nearly 0% of the company’s market capitalization.
99 institutional holders increased their position in Vir Biotechnology Inc. [NASDAQ:VIR] by around 11,437,447 shares. Additionally, 24 investors decreased positions by around 1,804,500 shares, while 10 investors held positions by with 40,078,243 shares. The mentioned changes placed institutional holdings at 53,320,190 shares, according to the latest SEC report filing. VIR stock had 51 new institutional investments in for a total of 3,521,067 shares, while 16 institutional investors sold positions of 664,953 shares during the same period.